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Background. Variables influencing serum hepatitis C virus (HCV) RNA levels and genotype distribution in
individuals with human immunodeficiency virus (HIV) infection are not well known, nor are factors determining
spontaneous clearance after exposure to HCV in this population.
Methods. All HCV antibody (Ab)–positive patients with HIV infection in the EuroSIDA cohort who had stored
samples were tested for serum HCV RNA, and HCV genotyping was done for subjects with viremia. Logistic regres-
sion was used to identify variables associated with spontaneous HCV clearance and HCV genotype 1.
Results. Of 1940 HCV Ab–positive patients, 1496 (77%) were serum HCV RNA positive. Injection drug users
(IDUs) were less likely to have spontaneously cleared HCV than were homosexual men (20% vs. 39%; adjusted odds
ratio [aOR], 0.36 [95% confidence interval {CI}, 0.24–0.53]), whereas patients positive for hepatitis B surface antigen
(HBsAg) were more likely to have spontaneously cleared HCV than were those negative for HBsAg (43% vs. 21%;
aOR, 2.91 [95%CI, 1.94–4.38]). Of patients withHCVviremia, 786 (53%) carriedHCVgenotype 1, and 53 (4%), 440
(29%), and 217 (15%) carried HCV genotype 2, 3, and 4, respectively. A greater HCV RNA level was associated with
a greater chance of being infected with HCV genotype 1 (aOR, 1.60 per 1 log higher [95% CI, 1.36–1.88]).
Conclusions. More than three-quarters of the HIV- and HCV Ab–positive patients in EuroSIDA showed active
HCV replication. Viremia was more frequent in IDUs and, conversely, was less common in HBsAg-positive patients.
Of the patients with HCV viremia analyzed, 53% were found to carry HCV genotype 1, and this genotype was
associated with greater serum HCV RNA levels.
The course of hepatitis C virus (HCV) infection varies
widely after initial exposure. Although one-third of in-
dividuals may clear the infection spontaneously, the re-
maining persons have persistent viremia and develop
chronic hepatitis C [1–6]. In the former group, liver
function test results and hepatic tissue remain normal,
and HCV antibodies (Abs) are the only evidence of a
past encounter with HCV [7]. In contrast, most patients
with chronic hepatitis C show elevations in liver enzyme
levels as a consequence of hepatic inflammation, and
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many steadily progress to liver cirrhosis [5, 6, 8–10]. Although
serum HCV RNA levels and HCV genotype do not seem to sig-
nificantly influence the natural history of chronic hepatitis C,
these virological features largely affect therapeutic outcomes. In-
dividuals with low viral load and those infected with HCV geno-
type 2 or 3 respond significantly better to pegylated interferon
plus ribavirin than do subjects with high HCV RNA levels and
infection with HCV genotype 1 or 4 [11, 12].
Because of shared routes of transmission, coinfection with
HIV and HCV is relatively common [13–15]. In Western coun-
tries, liver disease due to HCV infection has become a leading
cause of morbidity and mortality in HIV-infected individuals
[16–19]. In this regard, the virological characterization of HIV-
infected patients positive for HCV Abs is important, given that
this information may help in making appropriate estimations
about the burden of liver disease and the costs of treatment in
this population, including the need for liver transplantation in a
subset of them. The aim of the present study was to virologically
characterize HIV-infected patients positive for HCV Abs in the
EuroSIDA cohort, in an attempt to establish the current burden
ofHCV-related disease and the expected clinical and therapeutic
outcomes derived from its main virological features.
METHODS
Patients. EuroSIDA is a prospective study of 14,310 HIV-1–
infected patients at 93 centers across Europe, Israel, and Argen-
tina; details have been reported elsewhere [20]. Briefly, for each
cohort the centers provide data on consecutive patients seen at
the outpatient clinics beginning in May 1994 until a predefined
number of patients is enrolled from each site. To date, 7 cohorts
of patients have been recruited. Data are collected prospectively
at clinical sites and are extracted and sent to the coordinating
center at 6-month intervals. For cohorts I–III, eligible patients
were those who had had a CD4 cell count500 cells/mm3 dur-
ing the previous 4 months. The CD4 cell count restriction was
removed for cohorts IV–VII. At recruitment, in addition to de-
mographic and clinical information, a complete antiretroviral
treatment history is obtained, togetherwith themost recentCD4
cell count and plasma HIV RNA measurements. At each
follow-up visit, details on all CD4 cell counts and plasma HIV
RNA valuesmeasured since the last follow-up visit are extracted,
as are the dates of starting and stopping each antiretroviral drug
received and the use of drugs for prophylaxis against opportu-
nistic infections. The dates of diagnosis of all AIDS-defining ill-
nesses, non–AIDS-defining malignancies, and other serious in-
fections are also recorded. The present analysis includes
follow-up to a median date of January 2007.
Information on HCV Ab status has been collected since 1997;
patients who died or were lost to follow-up before this date did
not routinely have information on HCV Ab status collected.
Centers that have determined HCV genotype or that have mea-
sured HCV RNA level can provide that information to the coor-
dinating center at any time. The EuroSIDA plasma repository
was set up in 1997 and collects plasma samples from all HIV-
infected patients at 6-month intervals. Patients with unknown
HCV Ab status and a stored plasma sample were identified in
2006, and HCV Ab status was determined. Patients who tested
positive for HCVAb were then tested for serumHCVRNA level
and genotype in a reference laboratory. In addition, patients
with unknown HCV genotype and stored samples were identi-
fied, and serumHCVRNA levels were tested and genotypingwas
performed.
Serum HCV RNA was investigated and quantified in HCV
Ab–positive samples by means of the Versant HCV RNA assay
(version 3.0; Bayer Diagnostics), which uses a signal amplifica-
tion procedure with a linear dynamic range of 615 to 1  107
IU/mL. This method uses multiple probes to match several se-
quences of the HCV genome, negating the potential for under-
estimation of some HCV genotypes due to mismatches caused
by genetic polymorphisms [21, 22].
HCV genotyping was performed using the LiPA HCV geno-
type assay (version 2.0; Innogenetics), which is a line probe assay
that simultaneously detects sequences in the 5' untranslated re-
gion (UTR) and the core region. The examination of the core
region along with the 5' UTR allows more-accurate discrimina-
tion between genotypes 1 and 6 and improves subtyping across
distinct genotypes [23–25].
Statistical analyses. Descriptive values are expressed as ab-
solute or median values with interquartile ranges. Categorical
variables were compared using the 2 test, and continuous vari-
ables were compared using nonparametric tests. Logistic regres-
sion was used to identify which variables were associated with
spontaneousHCV clearance andwithHCVgenotype 1 infection
andwhich genotype was themost common, after adjustment for
demographic (age, sex, HIV exposure group, ethnic origin, re-
gion of Europe, date of HCV Ab testing, and date of joining
EuroSIDA), clinical (prior AIDS, CD4 cell count, and plasma
HIV RNA level), and therapeutic factors (antiretroviral ther-
apy). The results are presented using odd ratios (ORs) and ad-
justed ORs (aORs). All data were analyzed using SAS software
(version 9.1).
RESULTS
Of the 14,310HIV-infected patients enrolled in EuroSIDA, 3375
(24%) were positive for HCV Ab. Stored specimens were not
available for 1435 of these patients, who were excluded from
further analyses. Excluded patients were more likely to be of
white ethnic origin compared with included patients (95% vs.
89%), more likely to originate from southern Europe/Argentina
(39% vs. 34%) or eastern Europe (37% vs. 23%), and less likely
to have started antiretroviral therapy (63% vs. 84%). No other
significant differences were noted between included and ex-
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cluded HCV Ab–positive patients. Samples were not available
because the sample had already been used for a different project
or because it was not collected at the center, predominantly be-
cause the patient had died or was lost to follow-up before the
plasma repository was set up.
The main characteristics of the 1940 HCV Ab–positive pa-
tients included in the present analyses are shown in table 1. HCV
genotype was determined by the central laboratory for 80% of
patients. Overall, 1496 patients (77% [95% confidence interval
{CI}, 75%–79%])were positive for serumHCVRNAand/or had
a known HCV genotype. For the comparison between the main
features of HIV-infected patients with chronic HCV viremia
with thosewho spontaneously clearedHCV, it is remarkable that
injection drug users (IDUs) were less likely to spontaneously
clear HCV than were men who had sex with men (MSM) (20%
vs. 39%), whereas patients whowere positive for serumhepatitis
B surface antigen (HBsAg) were more likely to clear HCV than
were those negative for HBsAg (43% vs. 21%). Finally, patients
from southern Europe/Argentina were less likely to have spon-
taneously cleared HCV than were those from the other regions
(18% vs. 22%–27%).
Table 2 shows the univariate and multivariate ORs for spon-
taneous clearance of HCV. All 26 patients with prior exposure to
interferon therapy who subsequently tested negative for HCV
RNA were excluded from this analysis. In the multivariate
model, females had 39% increased odds of spontaneous HCV
clearance comparedwithmales (aOR, 1.39 [95%CI, 1.06–1.81];
P  .017). Compared with MSM, any other exposure group
had decreased odds of spontaneous HCV clearance. This was
particularly true for IDUs, who had 64% reduced odds of HCV
clearance comparedwithMSM(aOR, 0.36 [95%CI, 0.24–0.53];
P  .001). Compared with patients from southern Europe/Ar-
gentina, subjects from central or northern Europe had increased
odds of spontaneousHCV clearance. This was particularlyman-
ifest for patients from northern Europe, who had 47% increased
odds of HCV clearance compared with those from southern Eu-
rope/Argentina (aOR, 1.47 [95% CI, 1.03–2.09]; P  .032). Fi-
nally, patients who were positive for HBsAg had increased odds
of spontaneous HCV clearance compared with those who were
negative (aOR, 2.91 [95% CI, 1.94–4.38]; P  .001).
Of patients with detectable serumHCVRNA, 786 (53%)were
infectedwithHCV genotype 1, and 53 (4%), 440 (29%), and 217
(15%)were infectedwithHCVgenotype 2, 3, and 4, respectively.
Mixed genotypes were recognized in only 4 (0.2%) patients with
viremia. Figure 1 shows the geographical distribution of HCV
genotypes across the different regions. Although HCV genotype
1 predominated in all regions, the proportion of patients with
HCV genotype 3 infection was significantly higher in eastern
Europe than in the rest of Europe. HCV genotype 2 was uncom-
mon and was mainly seen in the northern and central European
regions. Finally, HCV genotype 4 represented 15% of infec-
tions but was less frequent in the northern Europe region.
Table 3 shows the main characteristics of patients infected with
distinct HCV genotypes. The median viral load in patients for
whom the HCV genotype was known was 576,812 IU/mL; it was
500,000 IU/mL in 54%. By genotype, the median serum HCV
RNAvalueswere776,015, 685,258, 393,523, and389,000 IU/mLfor
HCV genotypes 1, 2, 3, and 4, respectively (P  .001).
Table 4 shows the univariate and multivariate odds of having
HCV genotype 1 infection compared with any other HCV geno-
type. In the multivariate model, females had decreased odds of
HCV genotype 1 infection compared with males (aOR, 0.76
[95% CI, 0.59–0.99]; P  .038), as did patients from eastern
Europe compared with those from southern Europe/Argentina
(aOR, 0.37 [95% CI, 0.25–0.56]; P  .001). Older patients had
decreased odds of HCV genotype 1 infection (aOR, 0.80 per 10
years older [95% CI, 0.68–0.94]; P  .008). Finally, patients
with a higher serumHCVRNA level had increased odds of HCV
genotype 1 infection compared with patients with a lower serum
HCVRNA level (aOR, 1.60 per 1 log higher [95%CI, 1.36–1.88];
P  .001).
Table 1. Main characteristics of 1940 HIV-infected patients
positive for hepatitis C virus (HCV) antibody.
Variable Total
Serum HCV RNA
PPositive Negative
Patients 1940 (100) 1496 (77) 444 (23) . . .
Sex .22
Male 1348 (69) 1050 (78) 298 (22)
Female 592 (31) 446 (75) 146 (25)
Age, median, years 37.2 37.5 37.0 .47
Risk group .001
IDUs 1399 (72) 1126 (80) 273 (20)
MSM 181 (9) 111 (61) 70 (39)
Heterosexuals 233 (12) 164 (70) 69 (30)
Other 127 (7) 95 (75) 32 (25)
Ethnicity .30
White 1734 (89) 1343 (77) 391 (23)
Other 206 (11) 153 (74) 53 (26)
Region .001
Southern Europe/
Argentina 654 (34) 536 (82) 118 (18)
Central Europe 466 (24) 339 (73) 127 (27)
Northern Europe 378 (19) 274 (72) 104 (28)
Eastern Europe 442 (23) 347 (79) 95 (21)
Serum HBsAg status .001
Positive 137 (7) 78 (57) 59 (43)
Negative 1483 (76) 1173 (79) 310 (21)
Unknown 320 (16) 245 (77) 75 (23)
Antiretroviral therapy .048
Yes 1685 (87) 1287 (76) 398 (23)
No 255 (13) 209 (82) 46 (18)
NOTE. Data are no. (%) of patients, unless otherwise indicated. HBsAg,
hepatitis B surface antigen; IDUs, injection drug users; MSM, men who have
sex with men.
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DISCUSSION
This study reports the rate of HCV infection chronicity, genotype
distribution, andviral load ina largegroupofHIV-infectedpatients
across Europe. In excess of three-quarters of HIV-infected patients
positive for HCV Ab showed active HCV replication. In HIV-
negative individuals, spontaneous HCV clearance occurs overall in
approximately one-third of cases [1–6]. Two factorsmight explain
the higher rate of chronicity we saw in the present HIV-infected
population. First, HIV-associated immunodeficiency could impair
effective immune control of HCV replication after initial exposure
[1, 26, 27], given that it has been shown in other immunocompro-
mised conditions. Second, IDUs represented the largest group of
HCVAb–positive patients in EuroSIDA, and repeated exposure to
HCV in them could have favored the establishment of persistent
HCV infection. Although innate and adaptive immune responses
might partially protect against repeated exposure toHCV[28], they
might be less effective for exposure to distinctHCVgenotypes or in
the settingofHIV infection[29].Given thatHCVviremiawasmore
frequent among HCV Ab–positive IDUs enrolled in EuroSIDA
than in HCV Ab–positive subjects infected through sexual contact
(whether homo- or heterosexual), we hypothesize that repeated ex-
posure to HCV rather than HIV-associated immunosuppression
was themost likely cause of the higher rate of HCV infection chro-
nicity noted on average in EuroSIDA patients. In fact, HCV expo-
sure must have preceded HIV infection in most cases, as has been
shown in other studies that have examined the incidence of HCV
andHIV infections in high-risk groups [30, 31].
Patients with markers of dual hepatitis B virus (HBV) and
HCV infections show a worse liver prognosis [32]. In our study,
HCV viremia was less frequent in persons with HBsAg than in
the rest of the population (54% vs. 75%). This observation is in
agreement with the findings of prior studies, in which viral in-
terference phenomena have been reported to account for recip-
rocal inhibition of HBV andHCV replication [33, 34]. It is note-
worthy that control of HBV replication with antiviral agents
does not seem to be associated with HCV rebound, while the
contrary may occur [35, 36]. The biological basis for this obser-
vation relies on the distinct cell cycles for HBV and HCV infec-
tion. Although the genetic material of HBV is relatively stable
within infected cells as covalently closed circular DNA, the RNA
of HCV can be found replicating in the cytosol only, where it is
subject to rapid degradation [37, 38]. Therefore, if HBV over-
takes HCV replication, there is a high chance of spontaneous
HCV eradication. In contrast, treatment of HCV infection with
pegylated interferon plus ribavirin may make previously avire-
mic HBsAg-positive patients prone to HBV rebound [36].
Of patients with active HCV replication, 53% were infected
with HCV genotype 1; this genotype was associated with higher
HCV RNA levels and male sex, and it was less prevalent in east-
ern Europe. Whether subjects infected with HCV genotype 1
have higher serumHCV RNA levels than do those infected with
other genotypes has been debated for a while. Only a few studies
have claimed such an association, as in a large US cohort of
individuals with hemophilia [39] and,more recently, in the RIB-
AVIC trial [40]. Although it has been claimed that underestima-
Table 2. Variables associated with spontaneous hepatitis C virus (HCV) clearance.
Variable
Univariate Multivariate
OR (95% CI) P aOR (95% CI) P
Female sex, vs. male 1.17 (0.93–1.48) .18 1.39 (1.06–1.81) .017
Older age, per 10 years 1.13 (0.99–1.28) .069 1.12 (0.96–1.32) .15
Exposure group
MSM 1.00 (reference) 1.00 (reference)
IDUs 0.39 (0.28–0.55) .001 0.36 (0.24–0.53) .001
Heterosexuals 0.66 (0.43–1.00) .050 0.65 (0.40–1.06) .084
Other 0.56 (0.34–0.93) .024 0.42 (0.24–0.73) .002
Serum HBsAg status
Negative 1.00 (reference) 1.00 (reference)
Positive 2.87 (1.99–4.15) .001 2.91 (1.94–4.38) .001
Unknown 1.25 (0.93–1.67) .13 1.34 (0.95–1.89) .093
Region
Southern Europe/Argentina 1.00 (reference) 1.00 (reference)
Central Europe 1.68 (1.25–2.26) .001 1.35 (0.95–1.91) .098
Northern Europe 1.80 (1.32–2.44) .001 1.47 (1.05–2.09) .032
Eastern Europe 1.26 (0.93–1.72) .14 1.15 (0.75–1.78) .52
NOTE. The model was adjusted for data source, ethnic origin, prior AIDS diagnosis, date of
testing, date recruited to EuroSIDA, CD4 cell count at date of HCV testing, and antiretroviral therapy.
aOR; adjusted odds ratio; HBsAg, hepatitis B surface antigen; IDUs, injection drug users; MSM, men
who have sex with men; OR, odds ratio.
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tion of viral load in persons infected with non-1 HCV genotypes
is the reason for this observation, at least when some amplifica-
tion methods are used, in our study serum HCV RNA level was
measured by a hybridization technique that usesmultiple probes
and with which all distinct HCV genotypes seem to be reliably
quantified [21, 22]. Therefore, we are confident about our find-
Figure 1. Distribution of hepatitis C virus genotypes in the distinct EuroSIDA regions.
Table 3. Main features of 1496 HIV-infected patients with chronic hepatitis C, stratified by hepatitis C virus (HCV) genotype.
Variable
HCV genotype
P1 2 3 4
Patients with genotype 786 (53) 53 (4) 440 (29) 217 (15) . . .
Male sex 569 (72) 37 (70) 300 (68) 144 (66) .24
Age, median, yearsa 37.1 40.9 37.7 36.2 .001
Risk group, IDUs 569 (72) 28 (53) 356 (81) 173 (80) .001
White ethnicity 695 (88) 49 (92) 409 (93) 190 (88) .046
Region .001
Southern Europe/Argentina 306 (57) 12 (2) 131 (24) 87 (16)
Central Europe 187 (55) 16 (5) 86 (25) 50 (15)
Northern Europe 153 (56) 23 (8) 85 (31) 13 (5)
Eastern Europe 140 (40) 2 (0.6) 138 (40) 67 (19)
Serum HBsAg positive 38 (5) 4 (8) 21 (5) 15 (7) .001
Started antiretroviral therapya 693 (88) 45 (85) 353 (80) 196 (90) .001
Serum HCV RNA levelb
Median, IU/mL 776,015 685,258 393,523 389,000 .001
Range, IU/mL 728–39,200,000 6772–7,692,310 787–51,999,959 2870–16,399,854 . . .
Level 500,000 IU/mL 444 (62) 31 (61) 183 (45) 84 (43) .001
CD4 cell count, median, cells/mm3 313 349 326 350 .21
Plasma HIV RNA level, median, log copies/mL 2.70 2.30 2.70 2.55 .10
NOTE. Data are no. (%) of patients, unless otherwise indicated. HBsAg, hepatitis B surface antigen; IDUs, injection drug users.
a At date of genotyping.
b Available only for 719 (91%), 51 (96%), 408 (93%), and 195 (90%) patients for genotypes 1, 2, 3, and 4, respectively.
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ing of higher serum HCV RNA levels in patients infected with
HCV genotype 1 than with genotype 3 or 4. Given that baseline
HCV load predicts treatment outcome [14], our observation
further emphasizes the difficulties of successfully treating HCV
genotype 1–infected patients.
Serum HCV RNA levels may vary after antiretroviral expo-
sure, with a trend toward increasing during the firstmonths after
the initiation of therapy and decreasing steadily thereafter [41–
43]. Moreover, differences may be seen between protease inhib-
itors (PIs) and nonnucleoside reverse-transcriptase inhibitors,
as was recently observed in the RIBAVIC trial [40], in which 379
HIV/HCV-coinfected patients were examined. Multiple linear
regression analysis identifiedHCV genotype 1 and PI-based reg-
imens as independent predictors of higher serum HCV RNA
levels.Moreover, it should be noted that antiretroviral therapy in
general was independently associated with lower HCVRNA lev-
els in the RIBAVIC analysis [40], a finding that we could not
reproduce in our study.
Several limitations of our study should be acknowledged.
First, HCV Ab status was not known for all patients, and plasma
samples were not available for all patients who were HCV Ab
positive. Patients withmissing dataweremore likely to have died
or to have been lost to follow-up during the earlier years of the
study. Second, 2 different data sources were used, and therefore
potential biases might have been introduced. It is important to
note that the plasma repository was set up in 1997, and it was
unlikely that the decision to send a sample for storagewas related
to HCV Ab status or genotype. Where data were available from
both the case report forms and the central laboratory, results
from the latest were used and taken as the most accurate results.
All models were adjusted for the data source, and overall sensi-
tivity analyses including only data from the central laboratory
showed results similar to those of the main analyses presented
here. Finally, we have no information on when patients were
infectedwithHCV, the duration of drug use in IDUs, or whether
IDUs were using injection drugs at the time blood was drawn.
Despite these limitations, we feel that this study provides a com-
prehensive overview of the epidemiology of HCV in HIV-
infected patients across Europe.
In summary, this extensive virological study of HIV-infected
patients positive for HCV Abs enrolled in EuroSIDA has shown
that nearly one-quarter of patients spontaneously cleared HCV
infection after initial exposure, although this rate was much
higher in MSM (39%) than IDUs (20%). Of patients with HCV
viremia, 53% were infected with HCV genotype 1, and this ge-
notype was associated with higher serum HCV RNA levels. Al-
together, these findings highlight the difficult-to-treat profile of
chronic HCV infection in HIV-positive individuals.
THE EuroSIDA STUDY GROUP
Study group members. Argentina:M. Losso (national coordi-
nator) and A. Duran, Hospital JM Ramos Mejia, Buenos Aires.
Austria: N. Vetter (national coordinator), Pulmologisches Zen-
trum der Stadt Wien, Vienna. Belarus: I. Karpov (national coor-
dinator) and A. Vassilenko, Belarus State Medical University,
Minsk. Belgium: N. Clumeck (national coordinator), S. De Wit
and B. Poll, Saint-Pierre Hospital, Brussels; .R Colebunders, In-
stitute of Tropical Medicine, Antwerp. Bulgaria: K. Kostov, In-
fectious Diseases Hospital, Sofia. Croatia: J. Begovac, University
Hospital of Infectious Diseases, Zagreb. Finland:M. Ristola (na-
tional coordinator), Helsinki University Central Hospital, Hel-
sinki. Czech Republic: L. Machala (national coordinator) and H.
Rozsypal, Faculty Hospital Bulovka, Prague; D. Sedlacek,
Charles University Hospital, Plzen. Denmark: J. Nielsen (na-
tional coordinator), J. Lundgren, T. Benfield, and O. Kirk, Pa-
num Institute, Copenhagen; J. Gerstoft, T. Katzenstein, A.-B. E.
Hansen, and P. Skinhøj, Rigshospitalet, Copenhagen; C. Peder-
sen,OdenseUniversityHospital, Odense; L. Oestergaard, Skejby
Hospital, Aarhus. Estonia: K. Zilmer (national coordinator),
West-Tallinn Central Hospital, Tallinn; J. Smidt, Nakkusosa-
Table 4. Variables associated with hepatitis C virus (HCV) genotype 1 infection.
Variable
Univariate Multivariate
OR (95% CI) P aOR (95% CI) P
Female sex, vs. male 1.25 (1.00–1.56) .050 0.76 (0.59–0.99) .038
Older age, per 10 years 1.00 (0.88–1.13) .94 0.80 (0.68–0.94) .008
Region
Southern Europe/Argentina 1.00 (reference) 1.00 (reference)
Central Europe 1.08 (0.82–1.42) .58 0.83 (0.59–1.16) .26
Northern Europe 1.05 (0.79–1.41) .73 0.90 (0.64–1.26) .54
Eastern Europe 1.97 (1.50–2.59) .001 0.37 (0.25–0.56) .001
Higher HCV RNA level, per 1 log higher 1.49 (1.29–1.71) .001 1.60 (1.36–1.88) .001
Prior AIDS, yes vs. no 0.82 (0.65–1.03) .086 1.22 (0.93–1.59) .15
NOTE. The model was adjusted for data source, ethnic origin, exposure group, serum hepatitis B surface
antigen serostatus, date of HCV genotyping, date recruited to EuroSIDA, and CD4 cell count at the date of HCV
testing. aOR, adjusted odds ratio; OR, odds ratio.
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kond Siseklinik, Kohtla-Järve. France: C. Katlama (national co-
ordinator), Hôpital de la Pitié-Salpétière, Paris; J.-P. Viard,
Hôpital Necker-Enfants Malades, Paris; P.-M. Girard, Hospital
Saint-Antoine, Paris; J.M. Livrozet, Hôpital Edouard Herriot,
Lyon; P. Vanhems, University Claude Bernard, Lyon; C. Pradier,
Hôpital de l’Archet, Nice; F. Dabis, Unité INSERM, Bordeaux.
Germany: J. Rockstroh (national coordinator), Universitäts
Klinik Bonn; R. Schmidt, Medizinische Hochschule Hannover;
J. van Lunzen and O. Degen, University Medical Center
Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; H. J.
Stellbrink, IPM Study Center, Hamburg; S. Staszewski, J. W.
Goethe University Hospital, Frankfurt; J. Bogner, Medizinische
Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne.
Greece: J. Kosmidis (national coordinator), P. Gargalianos, G.
Xylomenos, and J. Perdios, Athens General Hospital; G. Panos,
A. Filandras, and E. Karabatsaki, 1st IKA Hospital; H. Sambat-
takou, Ippokration Genereal Hospital, Athens. Hungary: D.
Banhegyi (national coordinator), Szent Lásló Hospital, Buda-
pest. Ireland: F. Mulcahy (national coordinator), St. James’s
Hospital, Dublin. Israel: I. Yust (national coordinator), D.
Turner, andM. Burke, Ichilov Hospital, Tel Aviv; S. Pollack and
G.Hassoun, RambamMedical Center,Haifa; S.Maayan,Hadas-
sah University Hospital, Jerusalem. Italy:A. Chiesi (national co-
ordinator), Istituto Superiore di Sanità, Rome; R. Esposito, I.
Mazeu, and C. Mussini, Università Modena, Modena; C. Arici,
Ospedale Riuniti, Bergamo; R. Pristera, Ospedale Generale Re-
gionale, Bolzano; F.Mazzotta andA.Gabbuti, Ospedale S.Maria
Annunziata, Firenze; V. Vullo and M. Lichtner, University di
Roma la Sapienza, Rome; A. Chirianni, E.Montesarchio, andM.
Gargiulo, Presidio Ospedaliero A. D. Cotugno, Monaldi Hospi-
tal, Napoli; G. Antonucci, F. Iacomi, P. Narciso, C. Vlassi, and
M. Zaccarelli, IstitutoNazionaleMalattie Infettive Lazzaro Spal-
lanzani, Rome; A. Lazzarin and R. Finazzi, Ospedale San Raf-
faele, Milan; M. Galli and A. Ridolfo, Osp. L. Sacco, Milan; A.
d’Arminio Monforte, Istituto Di Clinica Malattie Infettive e
Tropicale, Milan. Latvia: B. Rozentale (national coordinator)
and P. Aldins, Infectology Centre of Latvia, Riga. Lithuania: S.
Chaplinskas (national coordinator), Lithuanian AIDS Centre,
Vilnius. Luxembourg: R. Hemmer (national coordinator), T.
Staub, Centre Hospitalier, Luxembourg. Netherlands: P. Reiss
(national coordinator), Academisch Medisch Centrum bij de
Universiteit van Amsterdam, Amsterdam. Norway: J. Bruun
(national coordinator), A. Maeland, and V. Ormaasen, Ullevål
Hospital, Oslo. Poland: B. Knysz (national coordinator) and J.
Gasiorowski, Medical University, Wroclaw; A. Horban, Cen-
trumDiagnostyki i Terapii AIDS, Warsaw; D. Prokopowicz and
A. Wiercinska-Drapalo, Medical University, Bialystok; A.
Boron-Kaczmarska and M. Pynka, Medical Univesity, Szczecin;
M. Beniowski and E. Mularska, Osrodek Diagnostyki i Terapii
AIDS, Chorzow; H. Trocha, Medical University, Gdansk. Portu-
gal: F. Antunes (national coordinator) and E. Valadas, Hospital
SantaMaria, Lisbon; K.Mansinho, Hospital de EgasMoniz, Lis-
bon; F.Maltez,Hospital CurryCabral, Lisbon.Romania:D.Dui-
culescu (national coordinator), Spitalul de Boli Infectioase si
Tropicale; V. Babes, Bucarest. Russia: A. Rakhmanova (national
coordinator),Medical AcademyBotkinHospital, St. Petersburg;
E. Vinogradova, St. Petersburg AIDS Centre, St. Peterburg; S.
Buzunova, Novgorod Centre for AIDS, Novgorod. Serbia: D.
Jevtovic (national coordinator), Institute for Infectious and
Tropical Diseases, Belgrade. Slovakia: M. Mokrás (national co-
ordinator) and D. Staneková, Dérer Hospital, Bratislava. Spain:
J. González-Lahoz (national coordinator), V. Soriano, L.
Martin-Carbonero, and P. Labarga, Hospital Carlos III, Madrid;
B. Clotet, A. Jou, J. Conejero, and C. Tural, Hospital Germans
Trias i Pujol, Badalona; J. M. Gatell and J. M. Miró, Hospital
Clinic i Provincial, Barcelona; P. Domingo, M. Gutierrez, G.
Mateo, and M. A. Sambeat, Hospital Sant Pau, Barcelona. Swe-
den: A. Karlsson (national coordinator), Karolinska University
Hospital, Stockholm; P. O. Persson, Karolinska University Hos-
pital, Huddinge; L. Flamholc, Malmö University Hospital,
Malmö. Switzerland: B. Ledergerber (national coordinator) and
R. Weber, University Hospital, Zürich; P. Francioli and M.
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne;
B. Hirschel and E. Boffi, Hospital Cantonal Universitaire de Ge-
neve, Geneve; H. Furrer, Inselspital Bern, Bern; M. Battegay and
L. Elzi, University Hospital Basel. Ukraine: E. Kravchenko (na-
tional coordinator) and N. Chentsova, Kiev Centre for AIDS,
Kiev.United Kingdom: S. Barton (national coordinator), St. Ste-
phen’s Clinic, Chelsea and Westminster Hospital, London;
A.M. Johnson andD.Mercey, Royal Free andUniversity College
LondonMedical School, London (University College Campus);
A. Phillips, M. A. Johnson, and A. Mocroft, Royal Free and Uni-
versity College Medical School, London (Royal Free Campus);
M. Murphy, Medical College of Saint Bartholomew’s Hospital,
London; J. Weber and G. Scullard, Imperial College School of
Medicine at St.Mary’s, London;M. Fisher, Royal Sussex County
Hospital, Brighton; R. Brettle, Western General Hospital, Edin-
burgh.
Virology group. B. Clotet (central coordinator) plus ad hoc
virologists from participating sites in the EuroSIDA study.
Steering committee. F. Antunes, B. Clotet, D. Duiculescu, J.
Gatell, B. Gazzard, A. Horban, A. Karlsson, C. Katlama, B.
Ledergerber (chair), A. D’Arminio Montforte, A. Phillips, A.
Rakhmanova, P. Reiss (vice-chair), and J. Rockstroh.
Coordinating center staff. J. Lundgren (project leader), O.
Kirk, A.Mocroft, N. Friis-Møller, A. Cozzi-Lepri,W. Bannister,
M. Ellefson, A. Borch, D. Podlevkareva, C. Holkmann Olsen, J.
Kjær, L. Peters, and J. Reekie.
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